Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib European Journal of Nuclear Medicine & Molecular Imaging, 05/04/2012

Kobe C et al. – Early and late residual 18F–fluorodeoxyglucose (FDG) uptake, measured using different quantitative SUV parameters, are predictive factors for short–term outcome in patients with advanced non–small–cell lung cancer (NSCLC) treated with erlotinib. Additionally, low residual FDG and 18F–fluorothymidine (FLT) uptake early and late in the course of erlotinib treatment is associated with improved progression–free survival (PFS).

Read this article on European Journal of Nuclear Medicine & Molecular Imaging

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?